During the last session, Viking Therapeutics Inc (NASDAQ:VKTX)’s traded shares were 4.29 million, with the beta value of the company hitting 0.76. At the end of the trading day, the stock’s price was $26.34, reflecting an intraday loss of -5.86% or -$1.64. The 52-week high for the VKTX share is $89.10, that puts it down -238.27 from that peak though still a striking 7.33% gain since the share price plummeted to a 52-week low of $24.41. The company’s market capitalization is $2.96B, and the average intraday trading volume over the past 10 days was 3.78 million shares, and the average trade volume was 4.32 million shares over the past three months.
Viking Therapeutics Inc (VKTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.12. VKTX has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 1 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.32.
Viking Therapeutics Inc (NASDAQ:VKTX) trade information
Viking Therapeutics Inc (VKTX) registered a -5.86% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.86% in intraday trading to $26.34, hitting a weekly high. The stock’s 5-day price performance is -12.40%, and it has moved by -6.99% in 30 days. Based on these gigs, the overall price performance for the year is -62.13%. The short interest in Viking Therapeutics Inc (NASDAQ:VKTX) is 24.21 million shares and it means that shorts have 4.34 day(s) to cover.
The consensus price target of analysts on Wall Street is $110, which implies an increase of 76.05% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $74 and $110 respectively. As a result, VKTX is trading at a discount of -317.62% off the target high and -180.94% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -23.00%. While earnings are projected to return -57.98% in 2025.
VKTX Dividends
Viking Therapeutics Inc is due to release its next quarterly earnings on 2025-Feb-04. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Viking Therapeutics Inc (NASDAQ:VKTX)’s Major holders
Viking Therapeutics Inc insiders own 2.70% of total outstanding shares while institutional holders control 74.23%, with the float percentage being 76.29%. FMR LLC is the largest shareholder of the company, while 541.0 institutions own stock in it. As of 2024-06-30, the company held over 16.54 million shares (or 14.9835% of all shares), a total value of $876.8 million in shares.
The next largest institutional holding, with 10.1 million shares, is of VANGUARD GROUP INC’s that is approximately 9.7599% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $535.26 million.
